Construction and expression of retroviruses encoding dual drug resistance genes in human umbilical cord blood CD34+ cells

A series of retro viral vectors encoding humanmdr1 gene alone as wetl as in combination with either humanmgmt gene or human mutantSer ³¹-dhfr gene are engineered. The resultant retroviruses are used to transduce human umbilical cord blood CD34⁺ cetls. It has been shown that expression of dual drug resistance genes in transduced cetls confers a broad range of resistance to both kinds of corresponding drugs. These data suggest a rationale for the use of such double chemoresistance gene constructs in anin vivo model in which transduced hematopoietic cetls will acquire multiple protection against the cytotoxic side effects of combination chemotherapy and may have future application in chemoprotection of normal tissues, thus killing tumor cetls more effectivety.     

结直肠癌5-FU持续输注化疗

目的 :探讨结直肠癌的辅助化疗新方案。方法 :回顾分析 11例结直肠癌术后 5 - FU联用四氢叶酸钙连续 5天输注化疗病例。结果 :2例 1～ 3级恶心和呕吐 ;1例 2级腹泻 ;2例 1～ 2级口腔溃疡 ;2例 1级白细胞下降 ;1例 1级手足综合症 ;4例静脉炎 ;无因化疗副反应而推迟化疗或减量病例。结论 :5 - FU联用四氢叶酸钙便携式输注系统连续五天输注化疗其疗效已得美国 NIH肯定 ,我院临床经验此化疗方案副反应较小 ,使用方便 ,可提高病人化疗期生活质量     

经尿道电切除膀胱肿瘤42例报告

报告了经尿道电功除膀胱肿瘤（TURBT）42例,共50次,其中T1期41次,T2期7次,T3期2次;术后定期行膀胱镜检查和膀胱灌注噻哌化疗.随访结果：复发2例,再发5例,死亡4例.笔者认为;该手术简便,创伤小,恢复快,住院时间短或不需住院,可保留完整的膀胱,生命质量高.     

TP 和 GP 方案治疗晚期非小细胞肺癌的临床对照研究

目的观察紫杉醇联合顺铂（TP方案）和吉西他滨联合顺铂（GP方案）对临床III期、IV期非小细胞肺癌（NSCLC）的疗效和安全性。方法47例晚期NSCLC患者随机分成2组分别接受TP方案和GP方案进行全身化疗2个周期以上，其中Ⅲ期NSCLC患者30例，占63．8％，IV期NSCLC患者17例，占36．2％。结果TP和GP总的有效率分别为42．8％和40．5％，入组患者的不良反应都在可控制的范围。结论紫衫醇联合顺铂方案和吉西他滨联合顺铂方案均对临床III期、IV期非小细胞肺癌安全有效，均可作晚期非小细胞肺癌一线化疗方案。     

肿瘤病人化疗副反应的护理对策

目的探讨护理人员如何用优质服务来避免或减轻肿瘤病人化疗副反应的痛苦。方法针对化疗病人的胃肠道反应、骨髓抑制、黏膜皮肤反应、泌尿系毒性反应、脱发等方面进行优质护理。结果能及时避免或减轻肿瘤病人化疗副反应的痛苦。结论优质护理，能减轻化疗病人的痛苦，病人能坚持治疗，达到预期化疗效果。     

化疗相关白血病

化疗相关白血病(chemotherapy-related leukemia)有上升趋势.综述讨论了化疗相关白血病的发生率、类型、影响因素、发病机理和预后,为临床医师选择更合理的治疗方案,减少化疗相关白血病的发生提供参考.     

康艾注射液辅助乳腺癌患者术后化疗

目的探讨康艾注射液能否减轻乳腺癌患者术后化疗的毒副反应。方法随机设计两组乳腺癌术后患者作为研究对象,治疗组(n=47)采用康艾注射液40~60 mL加入5%葡萄糖或0.9%生理盐水250~500 mL稀释后静脉点滴,1次/d,30 d为1个疗程,同时合并全身化疗(AC方案),对照组(n=46)单用化疗。毒副反应按WHO标准评价。结果治疗组比对照组在血液学毒性方面明显下降(P<0.01)。结论康艾注射液可减少乳腺癌患者术后化疗的毒副反应,提高患者的生活质量。     

Clinical implications of p53 mutations

The ultimate goal of basic cancer research is to provide a theoretical foundation for rational approaches to improve cancer therapy. Our extensive insight into the biology of the p53 tumour suppressor and the clinical behaviour of tumours harbouring p53 mutations indicates that information concerning p53 will be useful in diagnosis and prognosis, and may ultimately produce new therapeutic strategies. At the same time, efforts to understand the clinical implications of p53 mutations have revealed conceptual and technical limitations in translating basic biology to the clinic. The lessons learned from p53 may lay the groundwork for future efforts to synthesize cancer gene function, cancer genetics and cancer therapy.